Interferon-gamma-induced dephosphorylation of STAT3 and apoptosis are dependent on the mTOR pathway

Peng Fang1, Vivian Hwa, Ron G Rosenfeld

  • 1Department of Pediatrics, Oregon Health and Science University, Portland, OR 97239-3098, USA. fangp@ohsu.edu

Insights

Interferon-gamma (IFN-gamma) inhibits prostate cancer cell growth and induces apoptosis by suppressing STAT3. This effect requires the mTOR pathway, not just the JAK/STAT1 pathway, offering new therapeutic insights.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • Interferon-gamma (IFN-gamma) has known anti-cancer properties.
  • Metastatic prostate cancer cells often exhibit activated signaling pathways like STAT3, Akt, and ERK1/2.
  • The precise molecular mechanisms underlying IFN-gamma's anti-cancer effects are not fully elucidated.

Purpose of the Study:

  • To investigate the signaling pathways involved in IFN-gamma's anti-proliferative and pro-apoptotic effects on human metastatic prostate cancer cells (M12).
  • To determine the role of the mTOR pathway in IFN-gamma-mediated STAT3 suppression and apoptosis.

Main Methods:

  • Treatment of M12 cells with IFN-gamma, IFN-alpha, and IFN-beta.
  • Inhibition of specific signaling pathways using rapamycin (mTOR), LY294002 (PI-3K), and PD98059 (MAPK).
  • Analysis of STAT3, Akt, ERK1/2, and STAT1 phosphorylation and expression levels.
  • Assessment of cell proliferation and apoptosis.

Main Results:

  • IFN-gamma significantly inhibited M12 cell proliferation and induced apoptosis, unlike IFN-alpha or IFN-beta.
  • IFN-gamma treatment led to the suppression of constitutive tyrosine-phosphorylated STAT3 (pY-STAT3).
  • Inhibition of the mTOR pathway (via rapamycin) or upstream kinases (PI-3K, MAPK) blocked IFN-gamma-induced pY-STAT3 dephosphorylation and apoptosis, while not affecting the STAT1 pathway.

Conclusions:

  • The mTOR pathway is critical for IFN-gamma-induced suppression of pY-STAT3 and subsequent apoptosis in prostate cancer cells.
  • IFN-gamma's anti-cancer activity involves pathways beyond the classical JAK/STAT1 signaling.
  • These findings provide novel insights into the molecular mechanisms of IFN-gamma and suggest potential therapeutic strategies targeting the mTOR pathway in prostate cancer.

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...